NCT04888429招募中2 期
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma：A Multi-center, Single-arm Study
Qian Chu8 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2021年7月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 28
- 试验地点
- 8
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.
详细描述
This trial enrolled patients with advanced or metastatic pulmonary sarcomatoid carcinoma. Patients will receive camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day. The primary endpoint is objective response rate (ORR) assessed by investigators per RECIST version 1.1. Key secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response, and safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically stage IIIB, IIIC, IV Pulmonary Sarcomatoid Carcinoma according to WHO criteria or diagnosed with non-small cell lung cancer with sarcomatoid carcinoma component (sarcomatoid component tumour cells can be spindle cells, and/or giant cells and/or heterogenous sarcomatous differentiation including rhabdomyosarcoma, chondrosarcoma, etc.) ；
- •Has no prior systemic therapy; (chemotherapy and/or radiotherapy is allowed as part of neoadjuvant/adjuvant therapy. Patients who have had recurrence or metastasis for more than 6 months from the end of neoadjuvant/adjuvant treatment would be enrolled ) ；
- •Patients must have at least one measurable lesion according to RECIST 1.1 ；
- •ECOG score 0-1 ；
- •Agree to provide tumour tissue samples for biomarker exploration (including but not limited to PD-L1 IHC or NGS testing) ；
- •Life expectancy more than 3 months;
- •Has adequate organ function；
排除标准
- •Imaging (CT or MRI) showed tumor invasion of major vessels. hemoptysis ≥ 2.5 mL within 1 month before the first dose;
- •Patients with EGFR-sensitive mutation (19Exondel/L858R), ALK, ROS1 gene rearrangement or fusion, BRAFV600E mutation, MET gene exon 14 skipping mutation;
- •Patients with active bleeding or bleeding tendency ；
- •With hypertension that cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure ≤ 140 mmHg/diastolic blood pressure ≤ 90 mmHg)；
- •Urine protein ≥ (+ +), and 24-hour urine protein ≥ 1.0g;
- •Presence of thrombotic disorder requiring anticoagulant therapy with warfarin or heparin, or requiring antiplatelet therapy (aspirin ≥ 300 mg/day or clopidogrel ≥ 75 mg/day) ；
- •Has multiple factors affecting the absorption of oral drugs, such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction
- •Has active central nervous system (CNS) metastases confirmed by CT or MRI
- •Subjects diagnosed immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy of non-related tumor within 7 days before the first dose; allowed physiological dose of glucocorticoid (≤10 mg/day Prednisone or equivalent);
- •Has active hepatitis B ;
- •Has severe infections within 4 weeks of the first dose of study treatment ;
- •Women who are pregnant or lactating ;
- •With grade II or above myocardial ischemia or myocardial infarction and poorly controlled arrhythmias (QTc interval ≥ 450 ms for males and QTc interval ≥ 470 ms for females). Subjects with grade III-IV cardiac insufficiency or with left ventricular ejection fraction (LVEF) less than 50% according to NYHA criteria;
- •Has known history of Human Immunodeficiency Virus (HIV)；
- •Has known allergy to Camrelizumab, or famitinib or any of accessories ;
研究组 & 干预措施
Camrelizumab + Famitinib
Experimental
Patients received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day.
干预措施: Camrelizumab (Drug)
Camrelizumab + Famitinib
Experimental
Patients received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day.
干预措施: Famitinib (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: about 24 month
Objective Response Rate using RECIST 1.1 criteria, Proportion of patients with CR and PR
次要结局
- Progression-free Survival(about 24 month)
- Overall Survival(about 24 month)
- Duration of response(about 24 month)
- incidence, type and severity of adverse events(From time of informed consent through treatment period and up to 30 days post last dose of study treatment (about 24 months))
- Disease control rate(about 24 month)
研究者
Qian Chu
Professor
Tongji Hospital
研究点 (8)
Loading locations...
相似试验
招募中
3 期
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT05042375Jiangsu HengRui Medicine Co., Ltd.450
招募中
2 期
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction AdenocarcinomaGastroesophageal Junction Adenocarcinoma (Siewert II-III)NCT06163729Cancer Institute and Hospital, Chinese Academy of Medical Sciences68
已完成
2 期
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaResectable Hepatocellular CarcinomaNCT04701060Tianjin Medical University Cancer Institute and Hospital31
Unknown
2 期
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCCHead and Neck Squamous Cell CarcinomaNCT04399785Xingchen Peng34
Unknown
不适用
Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC TreatmentLung Cancer Stage IINCT04970043Cancer Institute and Hospital, Chinese Academy of Medical Sciences58